DISCONTINUED

!This test requires professional lab infrastructure and staff. This test cannot be performed by private individuals and we do not sell the kits to such individuals. If you suspect you are infected with SARS-CoV-2, please contact your healthcare provider.

The COVID19-REAAD™ Anti- SARS-CoV-2 lgG ELISA kit is a valuable assay for the detection of IgG antibodies against SARS-CoV-2 nucleocapsid protein and spike 1 receptor-binding domain antigens. This kit provides qualitative and semi-quantitative data for the identification of immune responses to SARS-CoV-2 infection. It can be used to determine recent or prior exposure to SARS-CoV-2 and is useful for the research of SARS-CoV-2 immune responses and serological population surveys.

Ready to use Microplate coated with recombinant SARS-CoV-2 proteins, 12 strips x 8 microwells

20X Wash Buffer Concentrate

100X Positive Control

100X Negative Control

100X Reference Control

Ready to use Diluent

100X Anti-IgG HRP Conjugate

Ready to use TMB Substrate Solution

Ready to use Stop Solution

Resealable Bag for unused microwells

Instructions for use

 

The amount of reagents is sufficient for 5 optimal runs.

Antigen: Recombinant SARS-CoV-2 N protein and Spike 1 (RBD) 

Species: Human 

Sample type: Serum, Plasma

 

Assay Controls

For the assay to be valid:

  • OD450-630nm of the Blank control should be ≤ 0.200.
  • OD450-630nm of the Negative Control should be ≤ 0.300.
  • OD450-630nm of the Reference Control should be between 0.300 and 0.800.
  • OD450-630nm of the Positive Control should be ≥ 1.200.

 

Data Calculations

The antibody concentration titer [AU/mL] could be calculated as follows:

ODsample – ODblank

——————————-   X 1 = Conc. [AU/mL]

ODReference – ODblank

 

 Interpretation of Data:

Calculate the antibody concentration titer [AU/mL] for each test sample as described above.  Results are as follows:

Non-Reactive:  IgG Titer < 1.00 AU/mL

Borderline: IgG Titer ≥ 1.00 to 1.10 AU/mL

Reactive: IgG Titer > 1.10 AU/mL

In case of a borderline results, a secure evaluation is not possible. It is recommended the samples should be repeat tested in duplicate. If one or more results are reactive, the final interpretation of the specimen is reactive; if the repeat results are borderline or negative, the final interpretation is borderline and another specimen should be collected.